Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis

Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis

Abstract Background Sacituzumab govitecan is an antibody-drug conjugate that is FDA approved for refractory metastatic triple-negative breast cancer. It targets the human trophoblastic cell-surface antigen 2 (Trop-2) with SN-38, a topoisomerase I inhibitor, attached to the antibody [1]. SN-38 breaks...

Full description

Saved in:
Bibliographic Details
Main Authors: Geneva Guarin, Audrey Netzel, Karen Marie Flores, Arun Cumpelik, Ron Bose
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Nephrology
Subjects:
Sacituzumab
Govitecan
ATIN
AKI
Trop-2
Online Access:https://doi.org/10.1186/s12882-024-03828-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12882-024-03828-z

Similar Items